arrow
D

Daniéla Oliveira Magro

Universidade Estadual de Campinas
H指数:22
被引数:2,043

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liraglutide Modifies Gut Microbiota Without Modulating Doxorubicin-Induced Toxicity in Rats

利拉鲁肽在不调节多柔比星诱导毒性的情况下改变大鼠肠道微生物群

2026-04-270
OAAI
Vitamin D, vitamin D receptor gene polymorphisms, and inflammatory bowel disease outcomes: From molecular mechanisms to clinical application

维生素D、维生素D受体基因多态性与炎症性肠病结局:从分子机制到临床应用

2026-04-210
PRE
Real-World Comparative Effectiveness and Safety of Ustekinumab Versus Anti-TNF Agents as First- or Second-Line Biologics in Crohn's Disease: A Multicenter Observational Study

真实世界中,乌司木单抗相较于抗-TNF药物的作为克罗恩病的一线或二线生物制剂的疗效与安全性比较:一项多中心观察性研究

2025-12-010
PRE
Clinical effectiveness and safety of vedolizumab versus infliximab in biologic-naïve patients with ulcerative colitis: A comparative real-world multicentric observational study

维多珠单抗与英夫利昔单抗在未接受过生物治疗的溃疡性结肠炎患者中的临床有效性和安全性: 一项比较真实世界的多中心观察性研究

2025-10-010
OAAI
From gut to liver: Exploring the relationship between inflammatory bowel disease and metabolic dysfunction-associated steatotic liver disease

从肠道到肝脏:探索炎症性肠病与代谢功能障碍相关脂肪性肝病的关联

2025-09-270
PRE
Tofacitinib for ulcerative colitis in Brazil: a multicenter observational study on effectiveness and safety

托法替尼治疗溃疡性结肠炎的巴西研究:一项关于有效性和安全性的多中心观察性研究

2025-03-180
OA
Effectiveness, safety and predictors of response to vedolizumab as first- or second-line biological therapy in patients with ulcerative colitis: A real-world observational multicenter study.
2025-01-220
PRE
Effectiveness and Safety of Tofacitinib in the Management of Ulcerative Colitis: A Brazilian Observational Multicentric Study
2024-12-010
OA
Anti-TNF therapy for Ulcerative Colitis in Brazil: a comparative real-world national multicentric study from the Brazilian Study Group of IBD (GEDIIB)
2021-05-270
PRE